The lncRNA B3GALT5-AS1 Functions as an HCC Suppressor by Regulating the miR-934/UFM1 Axis

Accumulating evidence has demonstrated that long noncoding RNA (lncRNA) is importantly related to the occurrence and development of cancer. According to reports, the expression of B3GALT5-AS1 in hepatocellular carcinoma (HCC) is downregulated; however, the role of B3GALT5-AS1 in HCC is not yet clear. In this study, our purpose is to explore the biological function of B3GALT5-AS1 in HCC and its coupling mechanism with miR-934 and ubiquitin-fold modifier 1 (UFM1). We found that the B3GALT5-AS1 expression level was of significant reduction in both HCC tissues and cell lines; B3GALT5-AS1 overexpression (ov) may inhibit the malignant features of HCC. In addition, we demonstrated that miR-934 mimics could reverse the effect of B3GALT5-AS1 ov, which proved miR-934 was the downstream regulator of B3GALT5-AS1. Furthermore, si-UFM1 could reverse the effect of miR-934 inhibitor, which revealed the connection between them. Moreover, we found that B3GALT5-AS1 could keep down the PI3K/AKT pathway through UFM1. Our results demonstrated that B3GALT5-AS1 was an excellent HCC suppressant by regulating miR-934 and UFM1 to achieve negative regulation of HCC cell proliferation, invasion, and metastasis, indicating that B3GALT5-AS1 is a promising potential therapeutic target for HCC treatment.


Introduction
In recent years, the incidence and mortality of tumors have been increasing, and hepatocellular carcinoma (HCC) as a primary liver cancer with high mortality has attracted widespread attention [1]. Its incidence ranks 6th among systemic malignancies, and its mortality ranks 3rd. With the change of people's dietary habits and environmental pollution intensified, the incidence of HCC worldwide is rising rapidly, and the number of patients who die from HCC each year is as high as 800,000 [2,3]. At present, the etiology and exact molecular mechanism of HCC are not fully understood [4,5]. It is of great significance to find effective therapeutic targets and to explore the molecular mechanisms of HCC.
Long noncoding RNA (lncRNA) is a type of RNA molecules with a transcript length of more than 200 nt. It is generally believed that they do not encode proteins but participate in the regulation of protein-coding genes at the RNA level [6,7]. Research results in recent years have shown that lncRNA can participate in the biological processes of cell proliferation, migration, and apoptosis of many tumors including liver cancer through epigenetic regulation, transcription regulation, and post-transcriptional regulation [8][9][10]. LncRNA B3GALT5-AS1 is located on the 39597147-39612822 of chromosome 21q22.2, containing 4 exon regions; it is downregulated in multiple malignancies, such as colon cancer [11][12][13] and gastric cancer [14]. LncRNA B3GALT5-AS1 was reported that can repress cell growth and induce cell apoptosis. e downregulation of B3GALT5-AS1 promotes the tumorigenesis and cell invasion. ese studies indicate that lncRNA B3GALT5-AS1 can act as a potential biomarker in cancer.
MicroRNA (miRNA) is a class of endogenous noncoding RNA found in eukaryotes that have the function of regulating post-transcriptional gene expression [15]. It has been reported that miRNA can specifically recognize the 3′-UTR end of target mRNA and form a single-stranded noncoding RNA with a length of 18-22 nucleotides. en, the downstream target mRNA or the upstream gene is regulated and the translation process is blocked, which plays an important role in the behavior of malignant tumors [16]. More and more evidence has shown that noncoding RNAs such as lncRNA and miRNA are gradually emerging in the field of disease diagnosis and treatment and playing an important role in tumor regulation. e successful exploration of the interaction mechanism between the two may provide new ideas for the discovery of new tumor targets [17]. Ubiquitinfold modifier 1 (UFM1), a ubiquitin-like protein, has recently been related to tumor progression also [18,19]. However, the interaction between UFM1, miR-934, and lncRNA is not clear.
Here, we screened a newfangled lncRNA, B3GALT5-AS1, with lower expression functions as a HCC suppressor by regulating the miR-934 and UFM1 axis. e high expression of B3GALT5-AS1 in HCC cells is related to the good survival of HCC patients; overexpression of B3GALT5-AS1 could inhibit the malignant features of HCC. In addition, we demonstrated that B3GALT5-AS1 ov was negatively correlated with miR-934, miR-934 was negatively relevant to UFM1, and B3GALT5-AS1 ov was positively associated with UFM1. Moreover, we found that B3GALT5-AS1 could keep down the PI3K/AKT pathway through UFM1.
ese results indicate that B3GALT5-AS1 can be considered a potential therapeutic target for HCC.

Tissue Specimen.
is research protocol was approved by the Affiliated Hospital of Nantong University's Ethics Committee, and a total of 56 pathological tissues of the patients were selected. e tumor tissues and matched adjacent tissues of all patients were freshly collected, and the adjacent tissues were more than 2 cm from the edge of the tumor. After the specimens were obtained, they were placed in a cryotube and immediately stored in liquid nitrogen.

RNA Extraction and qRT-PCR.
e TRIzol reagent method was used to isolate total RNA from cultured cells and tissues for subsequent qRT-PCR, and the purity and concentration were measured by using a UV spectrophotometer [20]. And, the reverse transcription kit instructions are referred for reverse transcription of RNA into cDNA. e expression of B3GALT5-AS1 and UFM1 was detected by the ABI 7900HT RealTime PCR system using SYBR Green assays, and GAPDH was used as the internal control. e expression of miR-934 was measured using TaqMan MicroRNA Assays, and U6 was treated as an internal control. e cycle threshold (Ct) value was measured for quantification, and the 2 −ΔΔCt method was used for normalization. Each experiment was performed in triplicate. e primer sequences have been provided in Table 1.

Fluorescence In Situ Hybridization (FISH) Assay.
Hep3B cells were selected to determine the localization of B3GALT5-AS1; CY3-labeled probe for B3GALT5-AS1 was used. e nuclear stained by DAPI was blue under ultraviolet excitation, and the cy3 appears red. e detailed operations were followed under the official guideline.

CCK-8 Assay.
After the logarithmic growth phase cells were prepared into a single cell suspension of 1 × 10 4 cells/ ml, 100 μl per well of cells was inoculated into a 96-well plate and cultured at 37°C and 5% CO 2 saturated humidity. Cell proliferation was detected by a Cell Counting Kit-8 (CCK-8) assay (Dojindo) following manufacturer's instructions. Finally, the cell viability was analyzed by detecting the absorbance (OD) of each group at 450 nm wavelength.

Cell Colony Formation Assay.
After the cells in the logarithmic growth phase are made into a single cell suspension, 300 cells/well are seeded into a 6-well plate and cultured at 37°C and 5% CO 2 saturated humidity. After 2 weeks, the cells were fixed with methanol and stained with 1% crystal violet for 15 min. Finally, the number of cell colonies was counted.

Cell Apoptosis.
e apoptosis detection kit (KeyGEN) was used to detect cell apoptosis. e cells were incubated in a 6-well plate (1 × 10 5 cells per well) to the logarithmic growth phase. en, the cells were processed according to kit instructions and stored in 70% ethanol at 4°C overnight. After that, cell apoptosis was analyzed by flow cytometry (BD Biosciences, San Jose, USA).

2
Journal of Oncology 2.9. Cell Migration and Invasion Assay. After the logarithmic growth phase cells were prepared into a single cell suspension of 1 × 10 4 cells/ml, the chambers were divided into two groups, i.e., without Matrigel and with Matrigel, and cell migration and invasion were detected, respectively. e finally migrated cells were fixed with ethanol, and then the cells were counted after staining with 0.1% crystal violet. For the wound-healing assays, cells were seeded in a 24-well plate at density of 1 × 10 6 and incubated for 24 h to adhere. en, a 200 μl sterile pipette tip was used to scrape the adherent cells to form fissures; they were washed three times with PBS, and the wound healing was observed under a microscope after incubating for 48 h. e finally migrated cells were fixed with ethanol and then imaged after staining with 0.1% crystal violet (Olympus, Japan).

RNA Immunoprecipitation.
e Magna RIP RNA-Binding Protein Immunoprecipitation Kit was used for RIP assay. To detect the miRNA binding to lncRNA, Hep3B cells were lysed in RIP lysis buffer and incubated with a biotin-coupled probe of B3GALT5-AS1 or oligo probe that was prebound on magnetic beads. e purified miRNA was then subjected to qRT-PCR. To detect the lncRNA binding to miRNA, the biotin-coupled probe of miRNA-934 or Biotin-NC was processed through the same protocol.

Vector Construction and Luciferase Reporter Assay.
e binding sites of B3GALT5-AS1 and UFM1 with miR-934 predicted by the bioinformatics tool were amplified by PCR, respectively. e amplified products were inserted into pGL3 plasmid to construct wild-type (wt) plasmids of B3GALT5-AS1 and UFM1, and the B3GALT5-AS1 and UFM1 mutant (mut) plasmids were constructed using a site-directed mutagenesis kit (Takara, Japan). For luciferase reporter assays, luciferase activity was measured through the Dual-Luciferase Reporter Assay system (Promega Corporation) after transfected the miR-934 mimics with the wild-type and mutant-type plasmids of the above configuration for 48 h.

Western Blot.
e cells were lysed on ice, and the total cell protein was extracted by centrifugation. e protein concentration was detected by the BCA method, and the loading buffer was added to the protein sample and heated to denature. Proteins were analyzed by 10% SDS-PAGE gel and transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad). en, the membrane was incubated with primary antibodies against UFM1, p-PI3K, t-PI3K, p-AKT, t-AKT, Bcl-2, Bax, Vimentin, E-cadherin protein, or GAPDH (Abcam) overnight at 4°C, followed by incubating with conjugated secondary antibody for 2 h. Finally, the membrane was placed with the luminescent agent into the imager for imaging.

Mouse Xenograft Model.
We used five-week-old BALB/ C nude mice to establish animal models; the cells were cultured and collected after digestion and centrifugation at first and then inoculated subcutaneously with 200 μl of each mouse at a density of 5 × 10 5 /100 μl. In the process of tumor growth, the length (L) and width (W) were measured using a caliper, and the volume of the tumor was calculated using the following formula: V � (L × W 2 ) × 0.5. 20 days after the injection, the animals were euthanized and tumor weight was measured. Animal experiments were approved by the Animal Ethics Committee of the Affiliated Hospital of Nantong University.
2.14. Statistical Analysis. SPSS 20.0 software and GraphPad 8.0 were used to statistically process the raw data obtained in the experiment, and the raw data obtained in the experiment were all expressed as mean ± standard deviation (SD). e independent sample t-test was used for the comparison between the two groups, and the one-way analysis of variance was used for the comparison between multiple groups.
e Kaplan-Meier test and log-rank analysis were used for survival analysis. P < 0.05 means that the difference is statistically significant.

B3GALT5-AS1 Is Downregulated in HCC Tissues and Cell
Lines. First, we screened differential expression lncRNAs for HCC through the GEO database (GSE138178, 49 HCC vs. 49 normal tissues) (Figure 1(a)), and the top 50 different lncRNAs for HCC are shown in Figure 1(b). Based on GEO data, we found that the expression of B3GALT5-AS1 in tumor tissues was lower than that of adjacent cancer tissues, indicating that high expression could suppress HCC progression (Figure 1(c)). To determine the expression of B3GALT5-AS1 in HCC tissues and adjacent normal tissues, we performed qRT-PCR in 56 HCC tissues and corresponding adjacent noncancerous tissues. As displayed in qRT-PCR assays, B3GALT5-AS1 expression was significantly downregulated in HCC tissues, with the average level over twofolds lower than that in normal tissues (Figure 1(d)). To examine B3GALT5-AS1 levels of HCC cell lines, qRT-PCR was performed in five human HCC cell lines (Hep3B, Focus, YY-8103, HCCLM3, and Huh7) and a control normal liver cell line (L02). e Table 1: Primers used in this study.
statistical analysis demonstrated that B3GALT5-AS1 expression was lower in HCC cells when compared with L02 cells and the expression in HCCLM3 and Hep3B was relatively lowest and highest, respectively ( Figure 1(e)). Moreover, compared with the higher B3GALT5-AS1 expression group, the Kaplan-Meier curve analysis of 56 patients showed that the lower B3GALT5-AS1 expression group was associated with a worse survival time in HCC patients ( Figure 1(f)). e result of FISH indicated that B3GALT5-AS1 was localized in the cytoplasm of Hep3B cell lines (Figure 1(g)). Furthermore, we studied the relationship between B3GALT5-AS1 expression and the clinicopathologic features of HCC patients. As shown in Table 2, B3GALT5-AS1 expression was significantly correlated to tumor size (P � 0.022) and TNM stage (P � 0.003). However, it was not related to age, gender, liver cirrhosis, HBsAg status, AFP, tumor multiplicity, and Edmondson grade.

B3GALT5-AS1 ov Inhibits HCCLM3 and Huh7 Cell
Proliferation, Migration, and Invasion. Given the downregulated B3GALT5-AS1 in both the HCC tissues and cell lines, we deduced that B3GALT5-AS1 may inhibit the growth of HCC. To clarify the biological function of B3GALT5-AS1 in HCC, we transfected the B3GALT5-AS1 overexpression plasmid into HCCLM3 cells and Huh7 cells, which were found to express the lower levels of B3GALT5-AS1 among the five HCC cell lines tested (Figure 1(e)). e transfection efficiency was confirmed by qRT-PCR, and the results demonstrated that B3GALT5-AS1 overexpression in HCCLM3 cells and Huh7 cells was successfully constructed. Obviously, the expression of B3GALT5-AS1 in the overexpression group was higher than that of NC group (P < 0.01, Figure 2(a)). CCK-8 assay showed that B3GALT5-AS1 ov dramatically suppressed cell proliferation in HCCLM3 cells and Huh7 cells compared with the NC  groups (P < 0.05, Figure 2(b)). Furthermore, the BrdU cell proliferation assay was consistent with the results of CCK-8 assay, identifying the cell inhibitory function of B3GALT5-AS1 in HCCLM3 cells (P < 0.01, Figure 2(c)). e cell colony formation assay showed that cell colonies of B3GALT5-AS1 ov groups were smaller than those of NC groups (P < 0.01, Figure 2(d)). e experimental results above collectively illustrated that B3GALT5-AS1 was validated in suppressing the cell proliferation of HCC from CCK-8, BrdU, and colony formation assay. Moreover, we found that the overexpression of B3GALT5-AS1 markedly promoted the apoptosis and inhibited in vitro migration and invasion capabilities of HCCLM3 and Huh7 cells (P < 0.01, Figures 2(e)-2(g)). e wound-healing assay showed that the overexpression of B3GALT5-AS1 significantly inhibited the migration of HCCLM3 cells (P < 0.01, Figure 2(h)). Collectively, our research discovered that the overexpression of B3GALT5-AS1 can significantly inhibit the malignant characteristics of HCC.

B3GALT5-AS1 Knockdown Potentiated Hep3B and YY-8103 Cell Proliferation, Migration, and Invasion.
To further analyze the effects of B3GALT5-AS1 on proliferation, migration, and invasion, we chose Hep3B and YY-8103 cells to construct B3GALT5-AS1 knockdown cell lines by transfecting si-B3GALT5-AS1 (Figure 1(e)). e si-B3GALT5-AS1 was applied for B3GALT5-AS1 silencing in the following experiments based on a higher knockdown efficiency of B3GALT5-AS1 in Hep3B and YY-8103 cells. qRT-PCR was executed to judge the successful construction of B3GALT5-AS1 knockdown cell lines (P < 0.01; Figure 3(a)). e CCK-8 assay and BrdU assay observed that the knockdown of B3GALT5-AS1 promoted cell proliferation rate in Hep3B and YY-8103 cells (P < 0.05, P < 0.01; Figures 3(b) and 3(c)). Similarly, the effect of downregulation of B3GALT5-AS1 on cell colony formation and migration in the presence of si-B3GALT5-AS1 was tested. e results showed the cell colonies in Hep3B and YY-8103 cells were larger after B3GALT5-AS1 silence (P < 0.01; Figure 3(d)). Compared with the si-NC groups, the si-B3GALT5-AS1 groups showed observably downregulated apoptosis and induced in vitro migration and invasion of Hep3B and YY-8103 cells (P < 0.01, P < 0.01, P < 0.01; Figures 3(e)-3(g)). e migration of cells was measured by the wound-healing assay, and the results demonstrated that the knockdown of B3GALT5-AS1 significantly promoted the migration of Hep3B cells (P < 0.01; Figure 3(h)). Taken together, these results indicate that the knockdown of B3GALT5-AS1 may enhance the malignant features of HCC, including cell proliferation, migration, and invasion.

B3GALT5-AS1 ov and Knockdown Can Inhibit and Potentiate Xenograft Tumor Growth In Vivo, Respectively.
To confirm whether B3GALT5-AS1 affects HCC in vivo, HCCLM3 and Hep3B cells were cultured and    Journal of Oncology subcutaneously injected into mice to construct overexpression and knockdown models. In the present study, it was hypothesized that the downregulation of B3GALT5-AS1 may lead to cancer progression and the occurrence of a malignant phenotype. As shown in Figures 4(a) and 4(b), we peeled off the tumor from the mice and took a physical picture. e results showed that the overexpression of B3GALT5-AS1 significantly inhibited tumor growth; on the contrary, the tumor grew vigorously after B3GALT5-AS1 silencing compared with the NC group. To quantify the extent of tumor growth, we measured average tumor volume and average tumor weight of the overexpression and knockdown groups. Interestingly, B3GALT5-AS1 overexpression effectively inhibits tumor volume and weight compared with the NC treated group, and the opposite is true after knockdown (P < 0.05, P < 0.05, P < 0.01, P < 0.01, Figures 4(c)-4(f )). Taken together, B3GALT5-AS1 overexpression and knockdown could suppress and promote xenograft tumor growth in vivo, respectively.

B3GALT5-AS1 Targeted miR-934 Directly and Negatively
Regulated miR-934. To determine whether the inhibitory effect of B3GALT5-AS1 overexpression is related to miRNA, we used target prediction software (http://www.microRNA. org/) to predict the sequence of potential B3GALT5-AS1-miRNA interactions, miR-934 was selected as a miRNA with a potential binding site to B3GALT5-AS1 ( Figure 5(a)). In order to further explore the association between B3GALT5-AS1 and miR-934 in HCC with luciferase report detection, we constructed B3GALT5-AS1-wt and B3GALT5-AS1-mut clones that have binding sites with miR-934 to pGL3. e experimental result of luciferase activity assay demonstrated the existence of direct interaction between miR-934 and B3GALT4-AS1 ( Figure 5(b)). RIP assay revealed that there was specific bind locations of B3GALT4-AS1 on miR-934 ( Figure 5(c)). e expression of miR-934 in liver cancer tissues is significantly higher than that in adjacent noncancerous tissues, which is the opposite of B3GALT5-AS1 in HCC (P < 0.01, Figure 5(d)). We also examined the expression of miR-934 in five human HCC cell lines (Hep3B, Focus, YY-8103, HCCLM3, and Huh7) and compared it to that in the normal liver cell line L02. e statistical analysis demonstrated that miR-934 expression was higher in HCC cells when compared with L02 cells and the expression of HCCLM3 and Hep3B was relatively highest and lowest, respectively ( Figure 5(e)). Furthermore, the results showed that miR-934 expression was significantly reduced after the     Journal of Oncology overexpression of B3GALT5-AS1 in HCCLM3 cells but was upregulated after the knockdown of B3GALT5-AS1 in Hep3B cells (P < 0.05, P < 0.05; Figures 5(f ) and 5(g)). ese results suggested that miR-934 was possibly a downstream target of B3GALT5-AS1 and was negatively regulated.

UFM1 Was Identified as a Target of miR-934.
To study the mechanism of miR-934 interacting with UFM1 in vitro, the wild-type and mutant-type sequences of UFM1 3′UTR bound to miR-934 were determined, and we found that there is an overlapping sequence between wt-UFM1 and miR-934 (Figure 7(a)), which suggested the interaction possibility of these two factors. To further explore the correlation by which UFM1 regulated miR-934 expression in HCC, we arranged luciferase activity assays to detect the association between UFM1 and miR-934. As shown in Figure 7(b), pGL3-UFM1wt plasmid and pGL3-UFM1-mut plasmid were cotransfected with miR-NC or miR-934 into HCC cells. Compared with the pGL3-UFM1-wt and miR-NC cotransfection group, the pGL3-UFM1-wt plasmid and miR-934 mimics   cotransfection significantly reduced the luciferase activity of the reporter plasmid, which indirectly elucidated the interaction of UFM1 and miR-934. ose results collectively illustrated that UFM1 is a regulatory target of miR-934. Additionally, the western blot results of 8 pairs of samples showed that the UFM1 expression in tumor tissues was significantly lower than that in adjacent tissues (Figure 7(c)).
To sum up, the present results illustrated that UFM1 was a target of miR-934.

UFM1 Downregulation Reverses the Inhibiting Effect of miR-934 Inhibitor in HCCLM3 Cells.
To investigate the adverse effect of si-UFM1 on the miR-934 inhibitor in the HCCLM3 cell line, we measured the expression of UFM1 in three groups (inhibitor NC, miR-934 inhibitor, and miR-934 inhibitor + si-UFM1) after transfection. e UFM1 mRNA expression level of the miR-934 inhibitor + si-UFM1 group was notably lower than that of only miR-934 inhibitor group (P < 0.01; Figure 8(a)). To verify the specific effects of UFM1 in hepatocellular carcinoma (HCC) and its influence toward miR-934, which include the proliferative, invasive capacity alteration with or without UFM1 silencing. CCK-8 assay further indicated that the suppression of miR-934 alleviated cell viability, while the downregulation of UFM1 could reverse this effect (Figure 8(b); * P < 0.05), which indirectly suggested that UFM1 was a tumor suppressor in HCC cells.  N1  T1  N2  T2  N3  T3  N4  T4   N5  T5  N6  T6  N7  T7  N8  T8 (c) cells with miR-934 suppression, but increased migration was presented in cells with UFM1 downregulation, which indicated si-UFM1 could reverse the decreased cell migration ability by the miR-934 inhibitor (P < 0.01). Similar effects were also observed in cell invasion (Figure 8(g); P < 0.01). Moreover, wound-healing assay exhibited augmented healing ratio in the cotreatment group than in the solo miR-934 inhibitor-treated group (Figure 8(h); P < 0.01). Conclusively, our experimental results collectively showed that UFM1 partakes in mediating HCC development progress.
3.9. B3GALT5-AS1 ov Inhibits the PI3K/AKT Pathway. In order to illustrate how B3GALT5-AS1 mediates the tumor behavior of HCC, we tested the activity of PI3K/AKT pathway, which is closely related to the proliferation and invasion of HCC cells. Western blot analyses revealed the expression levels of various proteins related to the activity of PI3K/AKT pathway. As shown in Figure 9, in addition to increased UFM1 expression when B3GALT5-AS1 ov in HCC cells, both of the phosphorylated AKT (p-AKT) and the phosphorylated PI3K (p-PI3K) decreased compared with the NC group and further affected the apoptosis pathwayrelated proteins Bcl-2 downregulation and Bax upregulation. Meanwhile, EMT pathway-related proteins are also affected, including E-cadherin upregulation and Vimentin downregulation. However, after we treated the si-B3GALT5-AS1, we found not only the increased phosphorylation of AKT and phosphorylation of PI3K but also the apoptosis pathway-related proteins Bcl-2 upregulation and Bax downregulation. Meanwhile, we also found the EMT pathwayrelated proteins E-cadherin downregulation and Vimentin upregulation. In summary, results suggested that B3GALT5-AS1 could suppress the EMT and promote apoptosis of HCC cells through suppressing the PI3K/AKT pathway, as shown in Figure 9.   (d) Cell colony formation assay of each group. (e) Apoptosis assays analyzed by flow cytometric provided that si-UFM1 could reverse the enhanced cell apoptosis ability brought by miR-934 inhibitor. e migration (f ) and the invasion (g) ability of HCCLM3 cells. (h) Woundhealing assays exhibited augmented healing ratio in the cotreatment group than in solo miR-934 inhibitor-treated group. * P < 0.05; * * P < 0.01.

Discussion
Liver cancer is one of the deadliest cancers in the world, and HCC accounts for more than 90% of liver cancer cases [21]. Radical resection is currently the preferred treatment for HCC, but most patients have undergone metastases in the liver and circulatory system during surgery. erefore, the continuous exploration of the molecular mechanisms of cancer occurrence and development and early intervention at the molecular level have become clinically urgent problems.
LncRNAs are a variety of noncoding RNAs containing the largest human genome, with transcripts exceeding 200 nucleotides in length. Although only 1% to 2% of transcription factors have the ability of protein translation, lncRNAs can participate in the body's epigenetic regulation through multiple channels such as chromatin remodeling, transcription regulation, and posttranscription [22,23]. HCC is a primary liver cancer with high mortality, so it is very important to find suitable therapeutic targets. Up to now, the expressions of lncRNA UCID [24], Tim3 [25], PDZD7 [26], DILC [27], FTX [28], ELF209 [29], HC [30], and HULC [31] indicate influential prognoses of HCC patients. B3GALT5-AS1 is the newly identified lncRNA, and the downregulation of B3GALT5-AS1 is often observed in human cancers. Accumulating data have indicated that the expression levels of lncRNA B3GALT5-AS1 are also reduced in colon cancer. Wang et al. found that the decreased expression of B3GALT5-AS1 in colon cancer tissues caused the metastasis and invasion of colon cancer cells, and the decreased expression of B3GALT5-AS1 is related to the poor prognosis of colon cancer patients [11]. Herein, lncRNA B3GALT5-AS1 expression levels were diminished in HCC compared with normal tissues and displayed a negative correlation, indicating that lncRNA B3GALT5-AS1 might be a negative factor in HCC, and the knockdown of B3GALT5-AS1 favors HCC cell proliferation, migration, and invasion, and the downregulation of lncRNA B3GALT5-AS1 can be used to predict survival in HCC.
More and more evidence shows that many dysregulated miRNAs exhibit carcinogenic or tumor suppressor effects on the occurrence and development of HCC and are potential diagnostic markers and new therapeutic targets for HCC [32,33]. According to reports, miR-934 has a promoting